CD135 Antibody (FITC)
364€ (100 tests)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
CD135 Antibody (FITC)
category
Primary Antibodies
provider
Abbexa
reference
abx139448
tested applications
FCM
Description
CD135 Antibody is a Mouse Monoclonal against CD135.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | CD135 |
| Host | Mouse |
| Reactivity | Human |
| Recommended Dilution | FCM: 4 µl/100 µl of whole blood or 106 cells. Optimal dilutions/concentrations should be determined by the end user.The content of a vial (0.4 ml) is sufficient for 100 tests. |
| Clonality | Monoclonal |
| Conjugation | FITC |
| Isotype | IgG1 |
| Clone ID | M931 |
| Size 1 | 100 tests |
| Tested Applications | FCM |
| Buffer | Stabilizing PBS solution containing 15 mM sodium azide. |
| Availability | Shipped within 5-12 working days. |
| Storage | Store in the dark at 2-8°C. Avoid exposure to light. Do not freeze. |
| Dry Ice | No |
| UniProt ID | P36888 |
| Gene ID | 2322 |
| Alias | Receptor-type tyrosine-protein kinase FLT3,FLK2,STK1,CD135,FLK-2,FL cytokine receptor,Fetal liver kinase-2,Fms-like tyrosine kinase 3,Stem cell tyrosine kinase 1 |
| Background | Antibody anti-FLT3 |
| Status | RUO |
Descripción
FLT3 (Fms-like tyrosine kinase 3), also known as CD135, is a cell-surface receptor primarily expressed on hematopoietic progenitor cells in the bone marrow and on certain immune cells, such as dendritic cells. Classified as a receptor tyrosine kinase (RTK), FLT3 belongs to the type III RTK family, which also includes the KIT, PDGFR, and CSF1R proteins. FLT3 plays a central role in the regulation of hematopoiesis by promoting the survival, proliferation, and differentiation of hematopoietic stem and progenitor cells (HSPCs). The FLT3 ligand (FLT3L) is the primary growth factor that binds to and activates FLT3, resulting in downstream signaling essential for immune cell development. FLT3 has attracted significant scientific interest due to its implication in hematologic malignancies, especially acute myeloid leukemia (AML). Mutations in the FLT3 gene, particularly internal tandem duplications (ITDs) and point mutations in the tyrosine kinase domain (TKD), are common in AML and are associated with a poor prognosis. Consequently, FLT3 is a prominent target in therapeutic research, with several FLT3 inhibitors under development or in clinical use for the treatment of FLT3-mutated AML.
Related Products
Human FLT3(Receptor-type tyrosine-protein kinase FLT3) ELISA Kit
Ver Producto
Mouse FLT3(Receptor-type tyrosine-protein kinase FLT3) ELISA Kit
Ver Producto